| Primary |
| Drug Use For Unknown Indication |
46.5% |
| Product Used For Unknown Indication |
15.6% |
| Heparin-induced Thrombocytopenia |
11.4% |
| Anticoagulant Therapy |
5.8% |
| Hypertension |
2.2% |
| Anaesthesia |
1.9% |
| Pulmonary Embolism |
1.9% |
| Anaphylactic Reaction |
1.5% |
| Heparin Neutralisation Therapy |
1.5% |
| Platelet Aggregation Inhibition |
1.5% |
| Pain |
1.2% |
| Thrombocytopenia |
1.2% |
| Arterial Thrombosis Limb |
1.0% |
| Depression |
1.0% |
| Haemorrhage |
1.0% |
| Hypersensitivity |
1.0% |
| Immunosuppression |
1.0% |
| Infection |
1.0% |
| Lymphoma |
1.0% |
| Peripheral Ischaemia |
1.0% |
|
| Haemorrhage |
13.6% |
| No Adverse Event |
9.1% |
| Angina Pectoris |
8.0% |
| Septic Shock |
6.8% |
| Thrombosis |
6.8% |
| Loss Of Consciousness |
5.7% |
| Thrombocytopenia |
5.7% |
| Peripheral Ischaemia |
4.5% |
| Renal Failure |
4.5% |
| Respiratory Failure |
4.5% |
| Subdural Haemorrhage |
4.5% |
| Aneurysm Ruptured |
3.4% |
| Gastrointestinal Haemorrhage |
3.4% |
| Hepatic Haematoma |
3.4% |
| Skin Exfoliation |
3.4% |
| Ventricular Tachycardia |
3.4% |
| Cardiac Arrest |
2.3% |
| Cardiovascular Disorder |
2.3% |
| Coagulation Time Prolonged |
2.3% |
| Deep Vein Thrombosis |
2.3% |
|
| Secondary |
| Drug Use For Unknown Indication |
35.7% |
| Hypertension |
10.9% |
| Heparin-induced Thrombocytopenia |
9.0% |
| Depression |
5.4% |
| Hypersensitivity |
5.4% |
| Pain |
5.4% |
| Product Used For Unknown Indication |
3.6% |
| Acute Coronary Syndrome |
2.7% |
| Anaphylactic Reaction |
2.7% |
| Anticoagulant Therapy |
2.7% |
| Trousseau's Syndrome |
2.7% |
| Deep Vein Thrombosis |
1.8% |
| Embolism |
1.8% |
| Haemorrhage |
1.8% |
| Peripheral Ischaemia |
1.8% |
| Pulmonary Embolism |
1.8% |
| Aortic Thrombosis |
1.4% |
| Atrial Fibrillation |
1.4% |
| Antiphospholipid Syndrome |
0.9% |
| Thrombocytopenia |
0.9% |
|
| Thrombocytopenia |
21.4% |
| Thrombotic Thrombocytopenic Purpura |
10.7% |
| Vena Cava Thrombosis |
10.7% |
| Renal Failure |
7.1% |
| Respiratory Failure |
7.1% |
| Skin Exfoliation |
5.4% |
| Loss Of Consciousness |
3.6% |
| No Adverse Event |
3.6% |
| Pericardial Effusion |
3.6% |
| Pleural Effusion |
3.6% |
| Subdural Haemorrhage |
3.6% |
| Thrombosis |
3.6% |
| Unevaluable Event |
3.6% |
| Graft Thrombosis |
1.8% |
| Heparin-induced Thrombocytopenia |
1.8% |
| Hypoaesthesia |
1.8% |
| International Normalised Ratio Increased |
1.8% |
| Leg Amputation |
1.8% |
| Stress |
1.8% |
| Venous Thrombosis |
1.8% |
|
| Concomitant |
| Drug Use For Unknown Indication |
16.9% |
| Coronary Artery Bypass |
8.5% |
| Heparin-induced Thrombocytopenia |
8.5% |
| Hypertension |
8.5% |
| Nuclear Magnetic Resonance Imaging |
8.5% |
| Product Used For Unknown Indication |
7.0% |
| Anticoagulant Therapy |
5.6% |
| Musculoskeletal Pain |
5.6% |
| Aortic Dissection |
2.8% |
| Aortic Valve Replacement |
2.8% |
| Atrial Flutter |
2.8% |
| Blood Pressure Decreased |
2.8% |
| Non-small Cell Lung Cancer |
2.8% |
| Pain |
2.8% |
| Pain Prophylaxis |
2.8% |
| Postoperative Analgesia |
2.8% |
| Renal Cancer Metastatic |
2.8% |
| Transplant Evaluation |
2.8% |
| Angiogram |
1.4% |
| Aortic Aneurysm |
1.4% |
|
| Anxiety |
20.0% |
| Heparin-induced Thrombocytopenia |
12.0% |
| Haemorrhage |
8.0% |
| Pneumoperitoneum |
8.0% |
| Vomiting |
8.0% |
| White Blood Cell Count Increased |
8.0% |
| Diarrhoea |
4.0% |
| Hepatic Vein Thrombosis |
4.0% |
| Nephrogenic Systemic Fibrosis |
4.0% |
| Pulmonary Embolism |
4.0% |
| Renal Failure |
4.0% |
| Renal Injury |
4.0% |
| Thrombocytopenia |
4.0% |
| Unevaluable Event |
4.0% |
| Weight Increased |
4.0% |
|
